Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
- Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
August 2, 2022
- Moderna Takes Over Spikevax’s Japan Marketing Authorization
August 2, 2022
- Japan’s Fertility Treatment Market to Grow 44.4% by 2025: Fuji Keizai
August 1, 2022
- Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
August 1, 2022
- Otsuka’s H1 Pharma Sales Rise 12% on Global Brands, Profits Drop 26.2%
August 1, 2022
- Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
August 1, 2022
- MSD Files 15-Valent Pneumococcal Vaccine for Pediatric Use in Japan
August 1, 2022
- Servier, Yakult to Wind Up Onivyde Promotion Deal in Japan
August 1, 2022
- Alnylam Japan Taps Ex-Galderma Chief Yutaka Okada as New President
July 29, 2022
- Shionogi Out-Licenses South Korea Rights of Cefiderocol to Local Firm
July 29, 2022
- Taiho Files Futibatinib for Biliary Tract Cancer Treatment in Japan
July 29, 2022
- Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
- JCR Files Growject for Short Stature due to SHOX Deficiency in Japan
July 29, 2022
- Takeda’s Q1 Sales Up 2.4% Despite Diabetes Divesture Last Year, Gets Hefty FX Gains
July 29, 2022
- Mochida to Quit Filgrastim Biosimilar as Repeated Price Cuts Made It Unprofitable
July 28, 2022
- Bayer, Employee Reach Settlement over Xarelto Scandal
July 28, 2022
- Kissei’s Global Plan for Fibroid Med Hits Snag as ObsEva Seeks Restructuring
July 28, 2022
- Ayumi to Curb Calonal Shipments amid Resurgence in COVID Cases
July 28, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…